Dystonia - Drug Pipeline Analysis and Market Forecasts to 2016
The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with dystonia, competitive assessment, product profiles of the major marketed products and promising drugs in the pipeline, implications for future market competition and the key players of the dystonia market. ( http://www.bharatbook.com/
The Dystonia Market is Forecast to Show High Growth Until 2016
The global dystonia market was worth $536m in 2009. The market is expected to grow by 19.4% during the next seven years to reach $1.9 billion by 2016. Although the drug pipeline for the treatment of dystonia is weak, the launch of Ipsen’s Dysport in early 2009, which is another breakthrough for dystonia sufferers, is the primary driver for increased market growth. The market remains well-served with more than four products, most of which are significantly efficacious in their respective target areas. Essentially, the global dystonia market is heading towards a phase of continuous growth, leveraging the current opportunities.
Competition in Dystonia Market is Strong
It found the current competition in the dystonia market to be strong. Allergan’s Botox continues to lead the market followed by Solstice’s Myobloc and Ipsen’s Dysport, accounting for about 80% of global dystonia sales. While the market remains well served by current the botulinum toxins, the newer candidates will have substantial scope for growth and profitability. Botulinum toxins are the most widely preferred and accepted choice of treatment for dystonia than the other drug classes such as anticholinergics and dopaminergics etc. Dysport, another neurotoxin, entered the market in April 2009. This was the only launch that the market has witnessed in the last seven years. Competition among the botulinum toxins is already fierce and may become more intense as more players enter the market, leading to a market share war.
Current Treatment Options Considerably Suffice the Market Demand
It found that although there is a narrow range of treatments, they still meet the current market requirements efficiently. Since the dystonia market is dominated by biologics, price has also been an area of concern. Biologics being premium priced have undoubtedly drawn a clear line and gained control over the dystonia market as the gold-standard therapy for dystonia. With the advent of Dysport and the other forms of botulinum toxins that are anticipated, the expectations from these therapies have increased. The lack of a cure will remain an unmet need in the market in the years to come.
Ignorance and Misdiagnosis Hinder Treatment
Even after the arrival of promising therapies for dystonia, it still remains a little unknown and often misdiagnosed condition. The cause of the disease is not known and there is no cure. The treatment options available are invasive, temporary and symptomatic. Due to the poor understanding of the disease, there are very few options directed towards the treatment of the disorder. The available treatments have been successful in treating the symptoms efficiently in both mild and severe forms of dystonia. There are two major concerns with the currently available dystonia treatments – safety and pricing. Since there are limited options for the treatment of dystonia, pipeline drugs with better efficacy, affordability, better patient compliance and safety profile are likely to achieve blockbuster status.
Weak Pipeline Incapable of Satisfying Unmet Need in the Near Future
This pipeline analysis revealed that there are seven candidates in the various stages of clinical development. Phase II has six pipeline molecules. There is only one molecule in Phase I, PurTox from Mentor, which is expected to be a promising candidate for dystonia. The pipeline molecules differ from each other in terms of mechanism of action. Ironically, the majority of the candidates which are under investigation have received prior approval for other indications. Since most of the research activities are being carried out the recognized universities, the pharmaceutical and biotechnology players are paying less attention towards the development of the molecules for dystonia. There are very few commercialization opportunities for the near future owing to a weak pipeline. Newer therapies therefore need to compete with biologics in order to be successful in the dystonia therapeutics market.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/
